A

ABL Bio Inc
KOSDAQ:298380

Watchlist Manager
ABL Bio Inc
KOSDAQ:298380
Watchlist
Price: 33 800 KRW -2.31% Market Closed
Market Cap: 1.6T KRW

ABL Bio Inc
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

ABL Bio Inc
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
A
ABL Bio Inc
KOSDAQ:298380
Net Income (Common)
-â‚©55.5B
CAGR 3-Years
-8%
CAGR 5-Years
-8%
CAGR 10-Years
N/A
Celltrion Inc
KRX:068270
Net Income (Common)
â‚©187.1B
CAGR 3-Years
-30%
CAGR 5-Years
-5%
CAGR 10-Years
7%
SK Bioscience Co Ltd
KRX:302440
Net Income (Common)
-â‚©50.1B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
H
Hugel Inc
KOSDAQ:145020
Net Income (Common)
â‚©112B
CAGR 3-Years
20%
CAGR 5-Years
18%
CAGR 10-Years
N/A
P
PharmaResearch Co Ltd
KOSDAQ:214450
Net Income (Common)
â‚©88.8B
CAGR 3-Years
24%
CAGR 5-Years
36%
CAGR 10-Years
N/A
Alteogen Inc
KOSDAQ:196170
Net Income (Common)
-â‚©2.9B
CAGR 3-Years
51%
CAGR 5-Years
18%
CAGR 10-Years
N/A

ABL Bio Inc
Glance View

Market Cap
1.6T KRW
Industry
Biotechnology

ABL Bio, Inc. engages in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2018-12-19. The major products include anti-angiogenesis antibodies anti-tumor targeting antibodies, T cell engager bispecific antibodies (TCEs), dual immune cell targeting bispecific antibodies (DICs), novel immune cell targeting antibodies (NICs), brain disease dual antibodies, antibody-drug conjugates (ADCs) , among others.

Intrinsic Value
9 717.33 KRW
Overvaluation 71%
Intrinsic Value
Price
A

See Also

What is ABL Bio Inc's Net Income (Common)?
Net Income (Common)
-55.5B KRW

Based on the financial report for Dec 31, 2024, ABL Bio Inc's Net Income (Common) amounts to -55.5B KRW.

What is ABL Bio Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-8%

Over the last year, the Net Income (Common) growth was -1 998%. The average annual Net Income (Common) growth rates for ABL Bio Inc have been -8% over the past three years , -8% over the past five years .

Back to Top